From the smallest biotech to the biggest pharmaceutical stock, The Motley Fool's Market Checkup covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.
In this segment from Tuesday's episode, health-care analyst David Williamson discusses Novartis , which has teamed up with Goldman Sachs to re-examine its businesses, and potentially sell off some of its divisions. David looks at Novartis' various divisions and discusses how the ones potentially on the chopping block contribute to the company as a whole, and he also compares this possibility with some other recent major Big Pharma spinoff deals.
Getting a handle on cancer
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
The article Will Novartis Rip Itself Apart? originally appeared on Fool.com.David Williamson owns shares of Novartis and Zoetis. Follow David on Twitter: @MotleyDavid. The Motley Fool recommends Goldman Sachs. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.